Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 17 - Drugs for dermatological disorders
Patents for A61P 17 - Drugs for dermatological disorders (106,455)
12/2003
12/04/2003WO2003099270A1 Methods of treating allergic reactions
12/04/2003WO2003099226A2 Antibody peg positional isomers, compositions comprising same, and use thereof
12/04/2003WO2003099221A2 Methods for using jnk inhibitors for treating or preventing disease-related wasting
12/04/2003WO2003099201A2 Compositions and methods of use for a fibroblast growth factor
12/04/2003WO2003099195A2 Immunomodulatory compounds and methods of use thereof
12/04/2003WO2003099192A2 Bis-aromatic alkanols
12/04/2003WO2003090818A3 Drug-delivery endovascular stent and method for treating restenosis
12/04/2003WO2003086309A3 NF-κB INHIBITORS
12/04/2003WO2003072062A3 Amino-substituted (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones for treating proliferative disorders
12/04/2003WO2003072013A3 Novel applications of statins in dermatology and corresponding pharmaceutical formulations
12/04/2003WO2003064596A3 Desaturase genes, enzymes encoded thereby, and uses thereof
12/04/2003WO2003063794A3 2,4-pyrimidinediamine compounds and their uses
12/04/2003WO2003045917B1 Ccr-3 receptor antagonists vii
12/04/2003WO2003039448A3 Polymer-structured composition containing lipophilic amino acid derivatives
12/04/2003WO2003039447A3 Composition containing an amino acid n-acylated ester and a polyamide-structured uv filter
12/04/2003WO2003028715A3 Methods using 1, 2-dithiol-3-thiones and their derivatives and metabolites for inhibiting angiogenesis
12/04/2003WO2003024406A3 Nestin-expressing hair follicle stem cells
12/04/2003WO2003022217A3 Treatment of excessive radiation (e.g. sunburn) exposure
12/04/2003WO2003018568A3 Ascorbic acid derivatives, methods of synthesis and pharmaceutical use thereof
12/04/2003WO2003017949A3 Novel synthetic ganglioside derivatives and compositions thereof
12/04/2003WO2003017941A3 Flexible applicator for applying oil-in-water emulsion with improved stability
12/04/2003WO2003015748A3 Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
12/04/2003WO2003008579A3 Polynucleotides expressed in dendritic cells and polypeptides encoded thereby
12/04/2003WO2003006996A3 Natural ligand of gpcr chemr23 and uses thereof
12/04/2003WO2003003971A3 Use of antidiabetics for making a medicine with cicatrizing effect
12/04/2003WO2002102310A3 Proteins associated with cell growth, differentiation, and death
12/04/2003WO2002098515A3 Topical treatments using alkanolamines
12/04/2003WO2002096444A3 Plumbago europaea constituents for use against psoriasis and hair loss
12/04/2003WO2002068397A8 Diaminoquinazoline esters for use as dihydrofolate reductade inhibitors
12/04/2003WO2002064827A3 Nucleic acids of the human abca12 gene, vectors containing such nucleic acids, and uses thereof
12/04/2003WO2002043774A3 Compositions and therapeutical use of polynucleotides encoding tcrs
12/04/2003US20030225450 Drug-delivery endovascular stent and method for treating restenosis
12/04/2003US20030225273 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
12/04/2003US20030225272 Novel mmp-2/mmp-9 inhibitors
12/04/2003US20030225164 Carbocyclic amines such as 4-(3-(4-Phenylcyclohexylamino)-propyl)phenol, administered as N-Methyl-D-Aspartate (NMDA) receptor inhibitors, for prophylaxis of cardiovascular, brain or nervous system disorders
12/04/2003US20030225152 Such as 3-phenylaminomethylene-1,3-dihydroindol-2-one; use treating cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases
12/04/2003US20030225151 Pyrazole compositions useful as inhibitors of ERK
12/04/2003US20030225147 Inhibit activity of protein kinases; for tumor growth, angiogenesis, viral infection, autoimmune disease or neurodegenerative disorder
12/04/2003US20030225138 3-(2,6-Dichloro-4-pyrydyl)-5-(substituted or nonsubstitutedbenzyl)- 2,4-imidazolidinedione derivatives useful for the treatment of inflammatory diseases
12/04/2003US20030225111 Use of a quinazoline derivative such as 1-(2,6-dichloro-phenyl)-3-(7-(3-morpholinopropoxy)quinazolin-4-yl) urea to produce an antiangiogenic and/or vascular permeability reducing effect
12/04/2003US20030225106 Prophylaxis and treatment of angiogenesis mediated diseases such as cancer
12/04/2003US20030225077 Naphthylamines used to chronic inflammatory diseases.
12/04/2003US20030225075 Novel pyrimidone derivatives
12/04/2003US20030225072 Opioid receptor active compounds
12/04/2003US20030225060 Acylated piperidine derivatives as melanocortin-4 receptor agonists
12/04/2003US20030225056 Triaryl-oxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
12/04/2003US20030225051 Also estrogen phosphonates, thiophosphonates, sulphonates, sulphonamides, and N-acylsulfamates
12/04/2003US20030225050 Process for production of crystals of 11ss-benzaldoxim-estra-4,9-diene derivatives, crystals obtained thereby and pharmaceutical preparations containing them
12/04/2003US20030224987 Binding to formyl peptide receptor or formyl peptide receptor-like 1
12/04/2003US20030224982 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
12/04/2003US20030224487 Novel cytokine zcytor17 ligand
12/04/2003US20030224075 Soy composition for balancing combination skin
12/04/2003US20030224072 Topical and oral administration of a composition containing Pelargonium Graveolens for diagnosis and treatment of various neuralgias and other conditions
12/04/2003US20030224014 Preparation and standardization of immunomodulatory peptide-linked glucans with verifiable oral absorbability from coriolus versicolor
12/04/2003US20030223991 Modulating activity of the immune system using agonists or antagonists of a CD200 receptor. Also provided are methods of treatment and diagnosis of immune disorders.
12/04/2003US20030223982 Enzymes in topical cosmetic or pharmaceutical compositions for the prevention of the ageing of human skin. In particular, the method prevents ageing effects caused by light. The method prevents the degradation of collagen within connective tissue
12/04/2003US20030223969 Method of modulating inflammatory response
12/04/2003US20030223941 Methods for modulating phototoxicity
12/04/2003CA2784937A1 Ccr9 inhibitors and methods of use thereof
12/04/2003CA2487557A1 Modulators and inhibitors of fibroblast growth factor receptor 5 polypeptides and gene expression thereof
12/04/2003CA2487303A1 Assays for modulators of asparaginyl hydroxylase
12/04/2003CA2487167A1 Combination of a dpp iv inhibitor and a cardiovascular compound
12/04/2003CA2487143A1 Regulation of novel human asparagine-hydroxylases
12/04/2003CA2487073A1 Methods for using jnk inhibitors for treating or preventing disease-related wasting
12/04/2003CA2487017A1 1,3-diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
12/04/2003CA2486853A1 Bis-aromatic alkanols
12/04/2003CA2486821A1 1-thia-3-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
12/04/2003CA2486376A1 Amino-pyridine, -pyridine and pyridazine derivatives for use as vanilloid receptor ligands for the treatment of pain
12/04/2003CA2486187A1 Kinase inhibitors
12/04/2003CA2485184A1 Methods for the identification of ikkalpha function and other genes useful for treatment of inflammatory diseases
12/04/2003CA2485166A1 Substituted pyrimidinone and pyridinone compounds
12/04/2003CA2484822A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
12/04/2003CA2484656A1 Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
12/04/2003CA2484288A1 Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
12/04/2003CA2484274A1 Compositions and methods of use for a fibroblast growth factor
12/04/2003CA2484000A1 Neutralizing human anti-igfr antibody
12/04/2003CA2478833A1 Anti-.alpha.v.beta.6 antibodies
12/03/2003EP1366771A2 Use of the neurotoxic compnent of botulinum toxins as a medicament
12/03/2003EP1366770A2 Use of botulinum toxin for treating muscle-associated pain
12/03/2003EP1366768A1 Compositions for therapeutic use comprising a vitamin, a metal salt and insulin or a growth hormone
12/03/2003EP1366765A1 Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing
12/03/2003EP1366763A1 Hydroxy diphenyl ether compounds as anti-inflammatory agents
12/03/2003EP1366743A1 Use of a derivative of 7-oxydated DHEA for treating dry skin
12/03/2003EP1366736A1 Cosmetics
12/03/2003EP1366180A2 Use of mutations of mec-1 and its related genes in the identification of compounds for treatment of disease
12/03/2003EP1366169A2 Antigenic proteins of shrimp white spot syndrome virus and uses thereof
12/03/2003EP1366162A2 Putative proteins and nucleic acids encoding same
12/03/2003EP1366161A2 Interleukin-8 homologous polypeptides and therapeutic uses thereof
12/03/2003EP1366079A2 Nuclear hormone receptor ligand binding domain
12/03/2003EP1366078A2 Ige receptor antagonists
12/03/2003EP1366075A2 New interferon beta-like molecules
12/03/2003EP1366063A2 Use of inhibitors of lyn-associated signal transduction (last) in the treatment of prostate cancr
12/03/2003EP1366036A2 Compounds having activity as inhibitors of cytochrome p450rai
12/03/2003EP1366028A1 Diaminoquinazoline esters for use as dihydrofolate reductase inhibitors
12/03/2003EP1366025A1 Agonists of beta-adrenoceptors
12/03/2003EP1366020A1 Urea derivatives having vanilloid receptor (vr1) antagonist activity
12/03/2003EP1366018A1 Omega-aminoalkylamides of r-2-aryl-propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells
12/03/2003EP1366012A2 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
12/03/2003EP1365800A2 Methods for using tetanus toxin for benificial purposes in animals (mammals)
12/03/2003EP1365798A2 Use of serp-1 in combination with an immunosuppressant for influencing inflammatory and immune reactions
1 ... 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 ... 1065